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Aims – Circulating extracellular vesicles (EV) are raising considerable interest as a non-invasive 2	
diagnostic tool as they are easily detectable in biological fluids and contain specific set of nucleic acids, 3	
proteins, and lipids reflecting pathophysiological conditions. We aimed to investigate differences in 4	
plasma-derived EV surface-protein profile as biomarker to be used in combination with endomyocardial 5	
biopsies (EMB) for the diagnosis of allograft rejection.  6	
Methods and results – Plasma was collected from 90 patients (53 training cohort, 37 validation cohort) 7	
prior to EMB. EV concentration was assessed by nanoparticle tracking analysis. EV surface antigens 8	
were measured using a multiplex flow cytometry assay comprising 37 fluorescently labelled capture bead 9	
populations coated with specific antibodies directed against respective EV surface epitopes. The 10	
concentration of EV was significantly increased and their diameter decreased in patients undergoing 11	
rejection as compared to negative ones. The trend was highly significant for both antibody-mediated 12	
rejection (AMR), and acute cellular rejection (P<0.001). Among EV-surface markers, CD3, CD2, ROR1, 13	
SSEA-4, HLA-I, and CD41b were identified as discriminants between controls and ACR, whereas HLA-14	
II, CD326, CD19, CD25, CD20, ROR1, SSEA-4, HLA-I, and CD41b discriminated controls from 15	
patients with AMR. ROC curves confirmed a reliable diagnostic performance for each single marker 16	
(AUC range 0.727-0.939). According to differential EV-marker expression, a diagnostic model was built 17	
and validated in an external cohort of patients. Our model was able to distinguish patients undergoing 18	
rejection from those without rejection. The accuracy at validation in an independent external cohort 19	
reached 86.5%. Its application for patient management has the potential to reduce the number of EMBs. 20	
Further studies in a higher number of patients are required to validate this approach for clinical purpose.  21	
Conclusions - Circulating EV are highly promising as new tool to characterize cardiac allograft rejection 22	
and to be complementary to EMB monitoring.  23	
 2 
NARRATIVE ABSTRACT - Our study describes a method for detecting and characterising circulating 24	
extracellular vesicles (EV) as a minimally invasive, liquid biopsy for the diagnosis of cardiac allograft 25	
rejection, and as a complementary tool to EMB monitoring. EV obtained from peripheral blood were 26	
profiled to identify rejection and its types in cardiac transplant recipients. A standardized and rapid tool 27	
was established using a fluorescent bead-based multiplex assay. We built a diagnostic model based on 28	
machine learning algorithms to identify non-rejecting patients who potentially do not require EMBs. EV 29	
profiling could represent a tool for non-invasive monitoring of allograft rejection in cardiac transplant 30	
recipients.  31	
 32	
Keywords: Extracellular Vesicles; Allograft Rejection; Heart Transplant; Biomarker; Machine 33	
Learning. 34	
 35	
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Allograft rejection remains a serious complication during and after the first post-transplant year(1, 2). 42	
More than 25% of patients have rejection episodes within one year and face the risk of developing 43	
consequent graft dysfunction with increased morbidity and mortality(3). Thus, early detection of cardiac 44	
allograft rejection is crucial to lower the risk of late morbidity and mortality.  The current gold standard 45	
for diagnosis and grading of rejection is via endomyocardial biopsy (EMB). EMB is performed either to 46	
confirm clinical diagnosis of allograft rejection, or routinely in asymptomatic patients, as surveillance 47	
 3 
monitoring for rejection(4, 5). EMB has also been used to evaluate efficacy of immunosuppression 48	
therapies in several clinical trials in which patients underwent more than 10 EMB during the first year 49	
after transplant(6, 7). This procedure still faces unresolved issues such as invasive risk, sampling error, 50	
and inter-reader variability(8-10). There is a long-standing effort toward the discovery of sensitive and 51	
noninvasive methods for the diagnosis of rejection that could be used in combination with tissue 52	
histology for reducing the frequency of biopsies(11). New, promising approaches are based on genomic 53	
screening, including microRNA(12, 13), and mRNA profiling(14). The non-invasive detection of 54	
circulating cell-free DNA (cfDNA)(15), or graft-derived cell-free DNA (GcfDNA)(16) were also 55	
proposed to diagnose acute cellular rejection (ACR), but not antibody-mediated rejection (AMR). 56	
Because nucleic acids and cell-free proteins are unstable in the circulation, a reliable quantification 57	
remains a critical problem. 58	
Cells secrete extracellular vesicles (EV) that are composed of bioactive molecules mediating intercellular 59	
communication processes(17) and activating intracellular signalling pathways of target cells(18, 19). EV 60	
released into the circulation and body fluids display different RNA, protein, and lipid contents reflecting 61	
the homeostatic state and function of EV-producing cells. A change in the pathophysiological status of 62	
tissues and/or organs affects the composition of circulating EV, resulting in a specific molecular 63	
signature(20-22). This is of particular interest with regard to acute inflammatory processes, since EV 64	
have emerged as key regulators in immune responses(23-25). In this context, EV have great potential as 65	
diagnostic biomarkers in various diseases, including cardiovascular diseases(22) and might represent a 66	
valuable tool to support EMB in the diagnosis of different types of cardiac rejection. Given its limited 67	
invasiveness, the profiling of blood-derived EV represents an interesting diagnostic approach for 68	
monitoring early, post-transplant status and for therapeutic management of patients. 69	
Here, we assessed, in a clinical setting, the potential of surface profiling of circulating EV for the 70	
diagnosis of acute cardiac allograft rejection, as companion biomarker to EMB monitoring. A multiplex 71	
 4 
flow cytometric assay using antibody-coated capture beads was used to investigate differences in EV 72	
antigen expression in patients with an EMB diagnosis of ACR or AMR. Differentially expressed EV-73	
surface antigens were combined in a single diagnostic model, based on machine learning algorithms, 74	
allowing for high accuracy discrimination between patients with and without graft rejection and among 75	
the different types of rejection. Finally, we validated our computational approach in an independent 76	
cohort of patients.  77	
 78	
METHODS 79	
A detailed description of patient data, EV isolation and characterization protocols, statistical analyses, 80	
and diagnostic modelling is provided in the Supplementary Appendix.  81	
Patient selection and blood handling 82	
Patients undergoing heart transplant were recruited at the Cardio-Surgery Center Gallucci (Dept. of 83	
Cardiac-Thoracic-Vascular Sciences and Public Health at the University Hospital of Padua, Italy). The 84	
study was approved by the local ethical committee and fully informed, written consent was provided by 85	
each patient. A total of 90 plasma samples were included and split into a training set (n=53) and a 86	
validation cohort (n=37). Patients with a first episode of rejection within 1 year since transplant were 87	
included in the study. Patients without rejection episodes within 1 year since transplant were enrolled as 88	
controls (Rejection 0, R0).  89	
Patients from the training cohort were retrospectively selected between February 2018 and March 2019, 90	
including only subjects with an unequivocal diagnosis at EMB. According to the ISHLT classification 91	
for ACR, we selected EMBs showing 2R or 3A grade that correspond to multifocal inflammatory 92	
infiltrate, and multiple foci of myocyte necrosis. For AMR diagnosis, we selected EMBs corresponding 93	
to pAMR 1(I+) or pAMR 2, in presence of positivity for circulating donor specific antibodies.  94	
For the validation cohort, we included 37 unselected consecutive patients, admitted for EBM between 95	
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April 2019 and January 2020, regardless of the final histologic diagnosis.  96	
We excluded, from both validation and training cohorts, patients with other acute or chronic 97	
inflammatory disease (e.g., auto-immune disease, cancer, active infections). 98	
All transplanted patients were ABO-compatible and were treated with cyclosporine, mycophenolate, and 99	
corticosteroids. All subjects enrolled in our study were scheduled for a surveillance biopsy in their regular 100	
follow-up after heart transplant in a setting of stable allograft function. Patients did not display any 101	
clinical signs/symptoms related to graft rejection (none of the patients was enrolled because rejection 102	
was suspected). Blood sampling was performed immediately before the EMB, thus avoiding potential 103	
confounding factors associated to procedure-related injury.  104	
The diagnosis of either ACR or AMR was defined, according to the International Society for Heart and 105	
Lung Transplantation guidelines (4, 5) (see Supplementary Appendix).  106	
Blood was collected in EDTA-treated tubes and centrifuged at 1,600 g for 15 minutes to separate plasma 107	
from cellular components; the low centrifuge speed avoided shear-stress-induced platelet activation. 108	
Plasma underwent serial centrifugation cycles to remove intact cells, cellular debris and larger EV: 109	
3,000 g for 20 minutes, 10,000 g for 15 minutes, and 20,000 g for 30 minutes (Figure 1A). Cleared, 110	
platelet-free plasma was finally stored at -80°C and not thawed prior to analysis. 111	
Plasma-derived EV quantification 112	
Presence of specific EV markers and absence of apolipoprotein contaminants were assessed by western 113	
blotting. Size and concentration of plasma EV were determined by nanoparticle tracking analysis (NTA) 114	
using NanoSight LM10 (Malvern Instruments, UK) equipped with a 405 nm laser and Nanoparticle 115	
Tracking Analysis NTA 2.3 analytic software. EV concentration is shown as EV/mL (median value, 116	
interquartile range).  117	
EV surface marker analysis by multiplex flow cytometry 118	
All	samples	underwent	bead-based	EV	immunocapture	and	were	analyzed	by	flow	cytometry	(FC),	119	
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using	 MACSPlex	 human	 Exosome	 Kit	 (Miltenyi	 Biotec,	 Germany),	 according	 to	 manufacturer’s	120	
instructions.	Median	fluorescence	intensity	(MFI)	was	measured	on	a	MACSQuant	Analyzer	10	flow	121	
cytometer	 according	 to	 previous	 validation	 studies(26-29). The multiplex platform analysis and 122	
gating strategy have previously been described(26, 28). MFI was evaluated for each subset of capture 123	
beads, corrected by subtracting the MFI of corresponding blank controls, and normalized by the mean 124	
MFI of CD9, CD63, and CD81. 125	
Statistical analysis and diagnostic modelling 126	
IBM SPSS Statistics 22 (IBM Corp., Armonk, New York, USA) and GraphPad PRISM 7.0a (La Jolla, 127	
California, USA) were used for statistical analyses. Scalar variables were analyzed with Kolmogorov–128	
Smirnov test to evaluate distributions. Normally distributed variables are expressed as mean ± standard 129	
deviation and were analyzed by ANOVA with post-hoc Bonferroni’s tests; non-normally distributed 130	
variables are expressed as median [interquartile range] and were analyzed by Kruskal-Wallis tests. 131	
Categorical variables are expressed as absolute number (percentage) and were compared with chi-square 132	
tests (Fisher’s exact test when sample size was ≤ 5). Correlations were evaluated by Pearson’s test (R 133	
coefficient) and analysis of regression curves. Receiver operating characteristics (ROC) curves were used 134	
to assess the area under the curve (AUC) and to compare diagnostic performances of selected variables; 135	
the Younden Index (J = sensitivity + specificity - 1) was calculated to assess the best sensitivity and 136	
specificity. P-values of less than 0.05 were considered significant.  137	
Machine learning supervised algorithms are exploited in clinical practice to formulate predictions of 138	
selected outcomes based on a given set of labeled, paired, input-output training sample data(30, 31). To 139	
build the diagnostic model, a random forest (RF) algorithm was created using Python 3.5 (library, scikit-140	
learn). The algorithm created 40 different classification trees; if at least 21 of 40 trees of the RF indicate 141	
the absence of rejection, the patient was classified as R0 (level 1); in case of detection of graft rejection, 142	
a second RF algorithm was created to distinguish ACR from AMR (level 2). A combined model was also 143	
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built to distinguish R0 vs. ACR vs. AMR, in a single step. Models were both internally and externally 144	
validated. Internal validation was provided by a leave-one-out cross-validation algorithm (see 145	
Supplementary Appendix). External validation was performed on an independent cohort enrolled in the 146	
same center. 147	
Protein interactor network analysis 148	
Protein interactors of the EV-surface marker were retrieved by Cytoscape PESCA plugin(32) and a 149	
global Homo sapiens protein-protein interaction (PPI) network of 1588 nodes and 36984 edges was 150	
reconstructed. For each quantitative comparison (R0 vs. ACR and R0 vs. AMR), a specific PPI sub-151	
network per comparison was reconstructed considering the first neighbors of each differentially 152	




We enrolled 90 subjects, 53 in the training cohort and 37 in the validation cohort. Patient characteristics 157	
are summarized in Tables 1, S1, and S2. All subjects enrolled were scheduled for a surveillance biopsy 158	
in their regular follow-up in a setting of stable allograft function.  159	
According to EMB parameters and biochemical analyses, patients from training cohort were divided in 160	
three groups (R0, ACR, AMR).  They were similar with respect to sex and age, whereas the time from 161	
heart transplant to rejection was 3 [2;8] months for the ACR group compared to 11 [9;14] months for the 162	
AMR group (P=0.004). Among AMR patients, 4 of 9 (44.4%) presented with capillary deposition of 163	
complement fraction C4d, and 2 of 9 (22.2%), with CD68-positive staining in macrophages with a 164	
grading >10%. The anti-HLA antibody assessment revealed all AMR patients as positive for anti-HLA-165	
II donor-specific antibodies (DSA) and anti-HLAII non-DSA. Moreover, 8 of 9 (88.9%) patients in the 166	
AMR group displayed a strong positivity for anti-HLA-I non-DSA. As expected, the cellular rejection 167	
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score was higher in patients with ACR compared to both controls and AMR patients. Biochemical 168	
parameters and the ejection fraction at echocardiography are reported in Table S2. For diagnostic 169	
modelling purpose, an independent cohort was enrolled. Clinical, biochemical, and EMB parameters did 170	
not significantly differ from the training cohort (Table S3). 171	
EV quantification 172	
The immunocapture assay was validated for its specificity to bind vesicles by western blotting analysis 173	
for the presence of specific EV markers such as TSG101 and CD81 and for the absence of contaminants 174	
such as apolipoprotein (ApoB48; Figure 1B). Given the reliability of the immunocapture protocol, we 175	
used the level of expression of tetraspanins CD9, CD63, and CD81 (generally accepted EV surface 176	
markers) for specific quantification of circulating EV. The MFI of tetraspanins was higher in patients 177	
with ACR and AMR, compared to R0 (P<0.001; Figure 1C and Table S4).  178	
Size and concentration profiles of circulating EV were determined by NTA. NTA confirmed a significant 179	
increase of the concentration of plasma-derived EV in patients undergoing rejection compared to subjects 180	
classified as R0; no differences were observed between ACR and AMR (Figure S1A and Table S4). 181	
Overall, the increase in the total number of EV reflects a concentration of the smaller subset (30-150 nm) 182	
that was approximately three-fold higher in ACR and AMR compared to R0 (P<0.01 for both 183	
comparisons; Figure S1A). Consistently, the median EV diameter was significantly lower in ACR and 184	
AMR vs. R0 (P<0.001; Figure S1B and Table S4). Cumulative distribution plots (EV concentration vs. 185	
particle size), resulted in a left-shift of curves and higher AUC for ACR and AMR as compared to R0 186	
(P<0.001 for both; Figure 1D).  Although NTA cannot distinguish EV from other particles such as 187	
lipoproteins, the analysis correlates with the antigenic quantification of CD9/CD63/CD81 (Pearson’s 188	
R=0.463; P<0.001; Figure 1E).  189	
Analysis of EV-surface markers  190	
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Immunocaptured EV from pre-cleared plasma of patients from the training cohort (n=53) were analyzed 191	
for the expression of 37 different surface antigens (Table S5). Several biomarkers were significantly 192	
higher in both ACR and AMR patients compared to R0 (Figure 2A). This applied for four antigens 193	
including the molecules of major histocompatibility complex class-I (HLA-I), the platelet membrane 194	
glycoprotein II-b (CD41b) and two non-immune system-related antigens: tyrosine-protein kinase 195	
transmembrane receptor (ROR1) and Stage-Specific Embryonic Antigen-4 (SSEA-4). Expression levels 196	
of two T-cell surface antigens, CD2 and CD3, that function as a cell adhesion molecule and a co-receptor 197	
activator, respectively, were differentially expressed between ACR patients vs. R0. In addition, the 198	
surface EV expression of five, well-established, immunologic markers was significantly higher in AMR 199	
patients as compared to R0: major histocompatibility complex class II (HLA-II), the epithelial cell 200	
adhesion molecule (CD326), B-lymphocyte antigens CD19 and CD20 and the interleukin-2 receptor 201	
alpha chain (CD25). Compared to R0, the heatmap highlights clusters corresponding to high MFI for 202	
CD2, CD3, ROR1, SSEA-4, HLA-I and CD41b in ACR patients, and to high ROR1, SSEA-4, HLA-I, 203	
CD41b, HLA-II, CD326, CD19, CD25, and CD20 in AMR patients (Figure 2B).  204	
Diagnostic Modelling 205	
The power of discrimination between patients presenting graft rejection and non-rejecting R0 controls 206	
was evaluated by analysis of ROC curves for each single, differentially expressed EV-surface marker. 207	
Overall, the MFI analysis displayed a reliable diagnostic performance for all the evaluated markers 208	
(Figure 3). Comparing ACR vs. R0, the best performance was obtained for HLA-I (AUC 0.939), CD3 209	
(AUC 0.848) and SSEA-4 (AUC 0.832), CD2 (AUC 0.829). Of note, the MFI for EV-carried HLA-I, 210	
CD2 and SSEA-4 displayed a sensitivity of 100% in the diagnosis of ACR, with specificities ranging 211	
between 63.6 and 87.9% (Figure 3A, and 3C). For AMR vs. R0, ROR1 showed the best performance 212	
with an AUC of 0.879 (sensitivity and specificity of 100% and 75.8%, respectively), followed by HLA-213	
I (AUC 0.872), SSEA-4 (AUC 0.820), CD20 (AUC 0.798), CD19 (AUC 0.795), HLA-II (AUC 0.788), 214	
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and CD41b (AUC 0.778). Strengthening our results, ROR1, SSEA-4, HLA-II and CD41b each achieved 215	
100% sensitivity, correctly identifying all patients with AMR (Figure 3B, and 3D). 216	
After having demonstrated excellent diagnostic performances for each candidate biomarker considered 217	
individually, we combined the 11 differentially expressed EV-surface antigens in a single diagnostic 218	
model using machine learning algorithms. A RF classification model was used as computational 219	
approach to identify patients with heart rejection using the MFI of circulating EV-carried antigens 220	
(Figure 4). The RF model was developed in the training cohort (n=53) and then internally validated by a 221	
leave-one-out cross-validation algorithm (see methods), which simulated how the model could generalize 222	
on an independent cohort. Finally, we performed a real external validation of the RF model on an 223	
independent cohort enrolled in the same center. 224	
At the training, a double level RF model was built as a first approach: the first level discriminated the 225	
presence of rejection (including both ACR and AMR) vs. no-rejection (R0) with an accuracy of 100%. 226	
All identified rejecting subjects (n=20), were then introduced in the second level, to distinguish between 227	
the two rejection types (ACR vs. AMR); this second model also provided a very high performance with 228	
an accuracy of 95%. All patients except one were correctly identified; a single patient with AMR was 229	
classified as ACR (Figure 4A). Next, we built a combined model to classify patients in one single step 230	
(R0 vs. ACR vs. AMR); all subjects were correctly allocated with an accuracy of 100% (Figure 4B). We 231	
then provided an internal validation by a leave-one-out cross-validation algorithm to simulate how the 232	
algorithms could perform in an independent cohort and to exclude overfitting bias (effect due to the best 233	
performance of the model in the cohort in which it is trained). The accuracy was still very high (83% to 234	
88.7%), with a modest overfitting effect (11.3% to 17%). Finally, we tested our model in an independent 235	
external validation cohort (Figure 5). Consistently with the internal validation, the accuracy was 86.5%, 236	
81.3%, and 78.4%, respectively for level 1, level 2, and combined RF models, thus confirming a reliable 237	
diagnostic performance even in an external cohort of patients.  238	
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The enrollment of consecutive unselected patients in the validation cohort, allowed us to simulate a 239	
clinical context in which EV profiling and random forest model were integrated not to avoid EMBs, but 240	
to select patients for this procedure. With this approach, we would have correctly managed 34 of 37 241	
patients (accuracy 91.9%), while reducing by 56.8% the number of EMBs required (Figure 6). 242	
Unfortunately, 3 rejecting patients would have been predicted as R0, thus missing the possibility to be 243	
correctly managed by EMBs. 244	
Correlation analyses  245	
Patients from training and validation cohorts were pooled and correlation analyses were performed to 246	
evaluate whether expression levels of EV-surface markers and EV concentration might relate to EMB 247	
findings and/or patient characteristics. Cellular rejection score correlates with EV concentration and with 248	
the expression level of SSEA-4, HLA-I, CD41b (R range 0.323-0.581, P<0.01) in patients with ACR. 249	
Significant correlations have been also found between circulating levels of anti-HLA-I (DSA and non-250	
DSA), and anti-HLA-II (DSA and non-DSA) antibodies and EV concentration, or MFI of ROR1 and 251	
HLA-I (R range 0.253-0.465, P<0.05; Table S6) in patients with AMR.  252	
Moreover, a significant correlation was found between lymphocyte counts and EV concentration. The 253	
number of lymphocytes and/or monocytes were also correlated to expression levels of HLA-II, CD25, 254	
HLA-I, SSEA-4, and CD41b in AMR and R0 patients, and to the expression of CD2, SSEA-4, and 255	
CD41b in ACR and R0 patients (Table S7). No significant correlations were observed between EV-256	
surface markers and age at heart transplant, or time to rejection onset.	 257	
A sub-analysis aiming to assess the sex-specific expression of EV surface antigens demonstrated a 258	
selective over-expression of CD3, CD19, CD2, CD25, and CD20 in rejecting females, whereas CD41b 259	
was over-expressed in male rejecting patients. In addition, the increase in EV concentration assessed by 260	
CD9/CD63/CD81 MFI was more relevant in female patients with rejection, as compared to males (Table 261	
S8).   Finally, we performed a correlation analysis between EMB findings and the expression of EV 262	
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markers. CD3, ROR1, SSEA-4, HLA-I, and CD41b MFI were directly correlated to the presence of 263	
inflammatory infiltrate, myocytolisis, myocyte necrosis, and/or vasculitis in ACR patients (R range 264	
0.239-0.513, P<0.05). HLA-II, SSEA-4, and HLA-I were correlated to the presence of inflammatory 265	
infiltrate and vasculitis in AMR patients (R range 0.238-0.462, P<0.05; Table S9). 266	
Protein interactor network analysis 267	
Since secreted EV have been shown to mediate autocrine, paracrine and endocrine signaling, we 268	
performed a theoretical analysis to predict possible protein-protein interactors.  The network analysis 269	
allowed identification of potential protein targets, biological pathways and molecular functions that could 270	
be affected by EV-surface markers that were differentially expressed in rejecting vs. not rejecting 271	
patients. “Hubs” and “bottlenecks” refer to proteins with greater numbers of protein connections or to 272	
those occupying critical network positions, suggesting pivotal roles for the management of information 273	
flow over the network (33) (Figure S1);. Except for HLA-E, hubs and bottlenecks in the interactor 274	
networks for ACR and AMR were different: ABI1, CD247, ERBB3, JUN, and B2M were identified as 275	
main interactors in ACR, whereas CD74, VAPA, SSR4, COPB1, PTCH1, DYNLL1, SGTA, RANBP9, 276	
and ITGA6 were main interactors in AMR (Tables S10, and S11). The higher number of EV-marker 277	
interactors in both ACR and AMR networks led to the enrichment of specific pathways related to the 278	
immune system and signal transduction, involving the inflammatory response, intercellular 279	
communication, cell survival, and apoptosis. 280	
 281	
DISCUSSION 282	
The present study highlights the diagnostic potential of circulating EV as biomarkers for monitoring 283	
cardiac allograft rejection. We found that the total amount of circulating vesicles assessed by the 284	
expression of specific surface antigens CD63, CD81, and CD9, discriminated between patients with and 285	
without rejection. Both ACR and AMR patients showed an increase in EV concentration, compared to 286	
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R0. Nanoparticle tracking analysis (NTA), which strongly correlated with the expression of tetraspanins 287	
(CD63, CD9 and CD81), showed an increase in EV concentration for rejecting patients, specifically for 288	
small-sized EVs (<150 nm, the size specifically associated with exosomes). These results are consistent 289	
with the notion that the inflammatory state induces the release of microvesicles (34). Most importantly, 290	
plasma-derived EV carry a specific set of surface antigens, reflecting the change in immunologic profile 291	
of heart transplant recipients. The level of expression of specific, membrane-associated markers 292	
significantly diverged in patients with no rejection from those with rejection, and above all, different 293	
types of rejection were discriminated by EV profiling. Eleven of 37 analyzed surface antigens were 294	
differentially expressed in patients with ACR and AMR compared to patients without rejection. Six 295	
markers identified a cluster of patients with ACR, whereas nine markers identified patients with AMR. 296	
Finally, ROC curves revealed high performances for the evaluated EV markers, with 100% sensitivity 297	
reached for several markers (HLA-I, CD2 and SSEA-4 for ACR; ROR1, SSEA-4, HLA-II and CD41b 298	
for AMR). The diagnostic potential was further improved by combining MFI values of the 11 EV surface 299	
antigens differentially expressed between groups through a machine learning approach.  300	
The accuracy of our computational approach resulted in a theoretical validation of ~89% and it stands at 301	
~87% when the validation was performed on a separate cohort of patients, with a negligible overfitting 302	
effect of about 2%.   303	
In light of what stated above, the immuno-profiling of plasma-derived EV and the integration of complex 304	
computational approaches in the management of patients after heart transplant, would help clinicians to 305	
discriminate between patients requiring EMB from those who may not require this procedure.  306	
The major strength of EV profiling approach is that it resulted in a consistent (it has been validated on 307	
patients) and reliable (with a relevant diagnostic performance) non-invasive diagnostic test, that can 308	
eventually reduce the number of biopsies for non-rejecting patients. By using the proposed model to 309	
simulate the management of subjects included in the validation cohort (37 consecutively enrolled 310	
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patients), introducing blood sampling and EV analysis before the EMB procedure, we could have reduced 311	
the number of patients selected for biopsy by 56.8% (flowchart in Figure 6). Unfortunately, three 312	
rejecting patients would have missed the possibility to be correctly managed through EMB.  313	
Another strength that should be considered in envisioning the profiling of EV	as	potential	diagnostic	314	
tool	lies in the fact that by analyzing systemic circulating particles, clinicians can quickly grasp a more 315	
complete picture of patient’s status. Indeed, differentially expressed markers on the surface of EV in 316	
blood may be more representative as compared	 to	markers detected in tissue sample, which can be 317	
distorted by necrosis and fibrotic areas.  Although, we did not select cardiac specific EV, as to date there 318	
is no specific antibody recognizing tissue specific vesicles, EV in blood presumably includes particles 319	
released from injured areas of tissue, but preferentially exclude necrotic areas in which circulation has 320	
ceased. 321	
Other studies have evaluated profiling of circulating EV to non-invasively monitor cardiac allografts for 322	
rejection. Kennel et al. performed proteomic analysis by liquid chromatography-tandem mass 323	
spectrometry on serum-derived exosomes (small EV) collected from heart transplant recipients with no 324	
rejection, ACR, and AMR(35). They found that allograft rejection alters the protein content of circulating 325	
exosomes, giving them unique protein expression patterns, which are suitable as predictive and 326	
prognostic biomarkers. Although very interesting, the approach used by Kennel at al. was based on 327	
relatively complex methodologies and instrumentation. Here we propose the profiling of the surface of 328	
EV which does not require lysis or digestion steps and can be performed using conventional flow 329	
cytometers.  Habertheuer et al. have recently shown that transplanted hearts release donor-specific 330	
exosomes. In a murine model of heterotopic heart transplant, they elegantly showed that the cardiac 331	
allograft releases a distinct pool of donor MHC-specific exosomes into recipient circulation. The signal 332	
peaked during early stages of acute rejection with high accuracy(36) enabling the development of a very 333	
specific and sensitive biomarker platform for allograft monitoring (36, 37). Compared to this study that 334	
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was carried out in a model of major histocompatibility mismatch using immunodeficient recipient mice, 335	
our platform has been analyzed in a clinical setting, including immunocompetent recipients on 336	
maintenance immuno-suppression, and provides comparable accuracy.   337	
Quantitative changes in microRNA cargo of serum exosomes from heart transplant recipients has also 338	
been demonstrated.  Dewi and colleagues showed that microRNA miR-142-3p increased in case of 339	
ACR(38). miR-142-3p is enclosed into secreted exosomes from T cells and targets specific messenger 340	
RNA in endothelial cells, thus implying a role for T cell-derived EV in mediating graft rejection(38). In 341	
line with this hypothesis, we found that CD3 and CD2, T cell co-receptors, were both upregulated on the 342	
surface of EV in patients with a diagnosis of ACR. It might be interesting, in the future, to assess whether 343	
the EV expressing these surface co-receptors also carry miR-142-3p. This scenario would reinforce the 344	
role of the endothelial-T cells axis in cell-mediated rejection.  345	
EV surface antigens may also reflect activation of B-cells. The receptor tyrosine kinase ROR1, which is 346	
a transmembrane protein highly expressed on the surface of leukemia cells, but not on normal B-347	
cells(39),(40), was significantly overexpressed in both AMR and ACR patients as compared to controls. 348	
However, none of the patients with rejection displayed proliferative hematologic disorders, thus ROR1 349	
expression on EV might reflect an activation state of B-cells, which is not associated with a malignant 350	
phenotype.  Given the correlation with clinical, biochemical, and EMB parameters we found significantly 351	
correlated between EV-surface markers and the numbers of circulating lymphocytes and monocytes in 352	
rejecting patients. The total number of WBCs was not increased in patients with a diagnosis of rejection, 353	
suggesting that EV number and profile may reflect the activation state of these cells and the systemic 354	
inflammatory response in transplant rejection(41). EV surface markers were also correlated with the 355	
presence of inflammatory infiltrate, myocytolisis, myocyte necrosis, and vasculitis on EMB, being 356	
associated not only to the diagnosis of ACR/AMR, but also to the severity of the inflammatory response 357	
triggered by rejection. 358	
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Although beyond the scope of the present paper, we hypothesized that EV antigens may exert active 359	
biological functions providing autocrine and paracrine signals to target cells (19, 42),(43). In this regard, 360	
we performed a theoretical interactor network analysis which suggested that the large majority of proteins 361	
up-regulated on EV of rejecting patients may have a potential role as ligand–receptor interactors for 362	
several intercellular pathways involved in the inflammatory response to graft rejection. For instance, 363	
circulating EV can act as extracellular stimuli for Jun (hub/bottleneck in ACR network), which controls 364	
a number of cellular processes including differentiation, proliferation, and apoptosis through the 365	
formation of heterodimer AP-1(44). This carries importance when considering that allograft treatment 366	
with decoy oligodeoxynucleotides (ODN) targeting the transcription factor AP-1 delays acute rejection 367	
and prolongs cardiac allograft survival in a rat transplant model(45). Interestingly, the network analysis 368	
highlighted a possible EV-mediated induction of genes related to natural killer (NK) cells and these 369	
findings are in line with recent tissue-based gene profiling unveiling the association of NK transcripts 370	
with chronic allograft vasculopathy in AMR (46). 371	
After stratification for sex, we found several EV markers selectively enriched in female rejecting patients. 372	
In particular, the overexpression of surface antigens CD19 and CD 20 (both markers of B-cells) is 373	
noteworthy, as it is known that estrogens amplify immuno-responses in women (47, 48). They act by 374	
increasing total number of progenitor B cells (49), and inducing B cell activation (50).  375	
The main limit of the present study is that the patients used for training and validation of the model did 376	
not allow us for longitudinal-based cohort study, thus limiting the evaluation of our model as predictive 377	
approach. Indeed, a longitudinal cohort would have allowed the demonstration of whether this approach 378	
may identify rejection before the diagnosis made by EMB, and whether changes in EV related parameters 379	
may even anticipate the histologic evidence of rejection, thus enabling the institution of an earlier and 380	
perhaps less intrusive treatment. A second important issue is the absence of specific, cardiac-derived 381	
antigens among the EV markers included in the analysis, thus excluding the possibility of grading the 382	
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vascular damage and cardiac damage related to rejection. Another potential limitation is the relatively 383	
small sample size. Our selection strategy at training was based on a well-defined histological pattern at 384	
EMB (see methods). This allowed us to evaluate highly selected patients and train the diagnostic model 385	
on subjects that truly underwent rejection. On the other hand, this can be a limitation as the training of 386	
the model does not include subjects with mild forms of rejection. However, the validation of the model 387	
was performed on an unselected cohort of patients, thus suggesting a potential clinical application, even 388	
if the present findings still have to be confirmed in larger prospective cohorts. Finally, we showed that 389	
different types of rejection are associated with different EV phenotypes, but we cannot define whether 390	
these phenotypes are specific for rejection, as the large majority of antigens might be theoretical 391	
associated with other acute and chronic inflammatory diseases.   392	
In conclusion, given its low cost, speed, and simplicity, as well as its high accuracy, the method here 393	
described provides a connection between allograft phenotypes, biochemical indexes, and histology 394	
parameters for the detection of different types of heart allograft rejection. Circulating plasma-derived EV 395	
are a highly promising tool for characterising and monitoring cardiac allograft rejection. It does not 396	
standalone as diagnostic biomarker that could completely replace EMB. The quantitative flow cytometer 397	
analysis and the computational approach proposed here can act in synergy with tissue histology and offer 398	
a tool to clinician for reducing the number of biopsies and selecting patients with the highest risk of 399	
rejection for a closer follow-up.	  400	
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Table 1 –Characteristics of patients from the training cohort. Sex, age at heart transplant (HT), 538	
endomyocardial biopsy (EMB) characteristics, cellular rejection score (RS) and HLA-I/II donor- specific 539	
and nonspecific antibodies (DSA) in patients from the training cohort, without rejection (R0; n=33), with 540	
cellular-mediated (ACR; n=11) or with antibody-mediated rejection (AMR; n=9). P-values of less than 541	
0.05 were considered significant (in bold). 542	
 543	
FIGURE LEGENDS 544	
Figure 1 – EV characterization. Characterization of circulating extracellular vesicles (EV) from patients 545	
of the training cohort with cellular-mediated rejection (ACR; orange; n=11), antibody-mediated rejection 546	
(AMR blue; n=9), compared to controls without graft rejection (rejection 0, R0; green; n=33). (A) Patient 547	
samples underwent serial centrifugation and then EV were characterized by nanoparticle tracking 548	
analysis (NTA) and standardized multiplex flow cytometry for the evaluation of 37 different EV surface 549	
antigens. (B) Western blot analysis of plasma and EV isolated by bead immuno-capture (n=4) for 2 EV 550	
markers (TSG101 and CD81) and a potential contaminant (Apolipoprotein, B48). (C) Median 551	
fluorescence intensity (MFI, %) of CD9, CD63, and CD81 by flow cytometric analysis. (D) Cumulative 552	
distribution plot combining EV concentration (n/mL; y axis) and diameter (nm; x axis). (E) Correlation 553	
between EV concentration and CD9-CD63-CD81 MFI. The regression line is depicted in red, with a 95% 554	
confidence interval. Data are expressed as median and interquartile range (panel C). P values < 0.05 were 555	
considered significant (*P < 0.05; **P < 0.01). 556	
 557	
Figure 2 – EV-surface markers. Median fluorescence intensity (MFI, expressed as a percentage [%], 558	
after normalization with mean MFI of CD9, CD63, and CD81) for differentially expressed EV surface 559	
markers in patients with cellular-mediated rejection (ACR; orange; n=11), antibody-mediated rejection 560	
 
	
(AMR; blue; n=9), or without graft rejection (rejection 0, R0; green; n=33). (A) EV surface markers were 561	
divided into three groups in which EV markers were significantly increased: in patients with ACR vs. R0 562	
(left), in patients with AMR vs. R0 (right), and both rejection groups vs. R0 (middle). Patients with ACR 563	
are represented in orange (n=11), AMR in blue (n=9), and the R0 group in green (n=33). Horizontal lines 564	
on the circles indicate significant increases compared to R0 (P < 0.05). (B) Heat map representing EV 565	
surface marker expression in patients stratified for diagnosis (red, low fluorescence; green, high 566	
fluorescence).. 567	
 568	
Figure 3 – Diagnostic performances of EV surface markers. Diagnostic performances of EV surface 569	
markers differentially expressed in patients without rejection (R0) compared to cellular-mediated 570	
rejection (ACR; n=44; panels A and C) and antibody-mediated rejection (AMR; n=42; panels B and D). 571	
The area under the curve (AUC), asymptotic difference compared to the referral line (dashed grey line), 572	
sensitivity, and specificity are reported for each marker. 573	
 574	
Figure 4 – Diagnostic Modelling. Random forest (RF) model for the diagnosis of allograft rejection 575	
using MFI values for the 11 EV surface markers differentially expressed among patients with cellular-576	
mediated rejection (ACR; orange; n=11), antibody-mediated rejection (AMR blue; n=9), compared to 577	
controls without graft rejection (rejection 0, R0; green; n=33). (A) Double level RF model. Level 1 578	
identifies patients with graft rejection, whereas Level 2 distinguishes between AMR and ACR. (B) 579	
Combined model discriminating between R0, ACR, and AMR in a single step. Representative 580	
classification trees and confusion matrix at training and internal validation of the model are reported for 581	




Figure 5 – External validation of random forest diagnostic models. The random forest models (level 584	
1, level 2, and the combined model) were validated on an independent external cohort (n=37). (A) Heat 585	
map representing EV surface marker expression in patients from the external validation cohort (n=37): 586	
acute cellular rejection (ACR; orange; n=13), antibody-mediated rejection (AMR; blue; n=4), or without 587	
graft rejection (rejection 0, R0; green; n=20).  (B, C, and D) Confusion matrix reporting accuracy, real, 588	
and predicted diagnosis, are reported for each model. Missed rejecting patients are underlined in red. 589	
 590	
Figure 6 – Simulated application of EV profiling in clinical practice. The random forest model (level 591	
1) was applicated to the validation cohort (n=37) to select patients for endomyocardial biopsy (EMB) 592	
(A) Management of heart transplanted patients using EMB as gold standard; all patients are correctly 593	
managed (accuracy 100%; number of EMB = 37). (B) Flow chart integrating EV profiling in patient 594	
management; 34 of 37 patients would be correctly managed (accuracy 91.9%; number of EMB = 16 [-595	
56.8%]); 3 patients (in red) were misclassified and would miss the possibility to performed EMB. 596	
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